A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer

Published:2006-05-23 Issue:6 Volume:58 Page:759-764
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Dragovich Tomislav,Mendelson David,Kurtin Sandra,Richardson Kelly,Von Hoff Daniel,Hoos Axel

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-006-0235-4.pdf

Reference26 articles.

1. Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectall cancer: evidence in terms of response rate. J Clin Oncol 10:896–903

2. Armand JP, Boige V, Raymond E, Fizazi K, Faivre S, Ducreux M (2000) Oxaliplatin in colorectal cancer: an overview. Semin Oncol 27:96–104

3. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

4. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413–1418

5. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autophagy-targeted drug delivery system in the management of cancer;Multifunctional Nanocomposites for Targeted Drug Delivery in Cancer Therapy;2024

2. Cancer nanomedicine: Recent developments in drug delivery systems and strategies to overcome eventual barriers to achieve a better outcome;Journal of Drug Delivery Science and Technology;2024-01

3. Recent advances in liposome-based targeted cancer therapy;Journal of Liposome Research;2023-10-09

4. Nano-particles’ benefits for colon cancer effective therapy: a review of recent advancements and clinical trials;International Journal of Polymeric Materials and Polymeric Biomaterials;2023-07-02

5. From Basics of Coordination Chemistry to Understanding Cisplatin-analogue Pt Drugs;Current Pharmaceutical Design;2023-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3